Monte Carlo calculation of the maximum therapeutic gain of tumor antivascular alpha therapy

Purpose: Metastatic melanoma lesions experienced marked regression after systemic targeted alpha therapy in a phase 1 clinical trial. This unexpected response was ascribed to tumor antivascular alpha therapy (TAVAT), in which effective tumor regression is achieved by killing endothelial cells (ECs)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medical physics (Lancaster) 2012-03, Vol.39 (3), p.1282-1288
Hauptverfasser:	Huang, Chen-Yu, Oborn, Bradley M., Guatelli, Susanna, Allen, Barry J.
Format:	Artikel
Sprache:	eng
Schlagworte:	ALPHA PARTICLES Alpha Particles - therapeutic use Biomedical modeling BISMUTH 213 BLOOD Blood Vessels - pathology Blood Vessels - radiation effects cancer CAPILLARIES Capillaries - pathology Cell membranes Cell nucleus Cell Survival - radiation effects cellular biophysics CLINICAL TRIALS Clinical Trials as Topic Diffusion dosimetry Dosimetry/exposure assessment endothelial cell Endothelial Cells - radiation effects ENERGY TRANSFER Geant4 Humans Melanoma - blood supply Melanoma - pathology Melanoma - radiotherapy MELANOMAS METASTASES MICRODOSIMETRY Monte Carlo Monte Carlo calculations MONTE CARLO METHOD Monte Carlo methods Monte Carlo simulations patient treatment probability RADIATION DOSES RADIOLOGY AND NUCLEAR MEDICINE RADIOTHERAPY Radiotherapy - methods Therapeutic applications, including brachytherapy Therapeutics Tissues TOXICITY tumor antivascular alpha therapy tumours
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!